Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes
LEHI, Utah, Oct. 23, 2025 /PRNewswire/ --Â Halia Therapeutics, Inc., a clinical-stage biopharmaceutical…
Halia Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
LEHI, Utah, Sept. 4, 2025 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage…
Scientists Discuss the Recent CancerVax Breakthrough
The Company's scientific team describes how they successfully disguised cancer cells and…
A New Chapter of Bold Leadership and Unstoppable Growth
LEHI, Utah, July 24, 2025 /PRNewswire/ -- Amare Global, The Mental Wellness…
Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
LEHI, Utah, June 4, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical…